Hypoglycemic Agents and Bone Health; an Umbrella Systematic Review of the Clinical Trials' Meta-analysis Studies

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Dec 24

PMID 39716250

Authors

Pouria Khashayar

Farid Farahani Rad

Ozra Tabatabaei-Malazy

Sara MohammadHosseinzadeh Golabchi

Patricia Khashayar

Mehdi Mohammadi

Sholeh Ebrahimpour

Bagher Larijani

Affiliations

Soon will be listed here.

Abstract

Background: No clear consensus exists regarding the safest anti-diabetic drugs with the least adverse events on bone health. This umbrella systematic review therefore aims to assess the published meta-analysis studies of randomized controlled trials (RCTs) conducted in this field.

Methods: All relevant meta-analysis studies of RCTs assessing the effects of anti-diabetic agents on bone health in patients with diabetes mellitus (DM) were collected in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). English articles published until 15 March 2023 were collected through the search of Cochrane Library, Scopus, ISI Web of Sciences, PubMed, and Embase using the terms "Diabetes mellitus", "anti-diabetic drugs", "Bone biomarker", "Bone fracture, "Bone mineral density" and their equivalents. The methodological and evidence quality assessments were performed for all included studies.

Results: From among 2220 potentially eligible studies, 71 meta-analyses on diabetic patients were included. Sodium-glucose cotransporter-2 inhibitors (SGLT-is) showed no or equivalent effect on the risk of fracture. Dipeptidyl peptidase-4 inhibitors (DPP-4is) and Glucagon-like peptide-1 receptor agonists (GLP-1Ras) were reported to have controversial effects on bone fracture, with some RCTs pointing out the bone protective effects of certain members of these two medication classes. Thiazolidinediones (TZDs) were linked with increased fracture risk as well as higher concentrations of C-terminal telopeptide of type I collagen (CTx), a bone resorption marker.

Conclusion: The present systematic umbrella review observed varied results on the association between the use of anti-diabetic drugs and DM-related fracture risk. The clinical efficacy of various anti-diabetic drugs, therefore, should be weighed against their risks and benefits in each patient.

References

Tsai W, Kong S, Lin C, Cheng K, Cheng Y, Chien M . Risk of fracture caused by anti-diabetic drugs in individuals with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract. 2022; 192:110082. DOI: 10.1016/j.diabres.2022.110082. View

Lecka-Czernik B . Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis. Curr Osteoporos Rep. 2010; 8(4):178-84. PMC: 2947013. DOI: 10.1007/s11914-010-0027-y. View

Yen F, Hsu C, Cheng-Chung Wei J, Hou M, Hwu C . Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Front Med (Lausanne). 2022; 9:839456. PMC: 8888965. DOI: 10.3389/fmed.2022.839456. View

Cheng L, Li Y, Hu W, Bai F, Hao H, Yu W . Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes Metab. 2019; 45(5):436-445. DOI: 10.1016/j.diabet.2019.01.010. View

Wu B, Fu Z, Wang X, Zhou P, Yang Q, Jiang Y . A narrative review of diabetic bone disease: Characteristics, pathogenesis, and treatment. Front Endocrinol (Lausanne). 2023; 13:1052592. PMC: 9794857. DOI: 10.3389/fendo.2022.1052592. View

Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M . Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018; 9:CD011798. PMC: 6513625. DOI: 10.1002/14651858.CD011798.pub2. View

Younes A, Salem M, Maraey A, Nomigolzar S, Sewell K, Khalil M . Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis. Int J Cardiol. 2022; 366:51-56. DOI: 10.1016/j.ijcard.2022.06.059. View

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

Loke Y, Singh S, Furberg C . Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2008; 180(1):32-9. PMC: 2612065. DOI: 10.1503/cmaj.080486. View

10.

Rajabi M, Ostovar A, Akbari Sari A, Sajjadi-Jazi S, Mousavi A, Larijani B . Health-Related Quality of Life in Osteoporosis Patients with and without Fractures in Tehran, Iran. J Bone Metab. 2023; 30(1):37-46. PMC: 10036187. DOI: 10.11005/jbm.2023.30.1.37. View

11.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

12.

Lou Y, Yu Y, Duan J, Bi S, Swe K, Xi Z . Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Ther Adv Chronic Dis. 2020; 11:2040622320961599. PMC: 7534105. DOI: 10.1177/2040622320961599. View

13.

McDonough A, Rosenthal R, Cao X, Saag K . The effect of thiazolidinediones on BMD and osteoporosis. Nat Clin Pract Endocrinol Metab. 2008; 4(9):507-13. DOI: 10.1038/ncpendmet0920. View

14.

Lee H, Hwang J . Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism. Curr Diab Rep. 2020; 20(12):78. DOI: 10.1007/s11892-020-01361-5. View

15.

Watts N, Bilezikian J, Usiskin K, Edwards R, Desai M, Law G . Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2015; 101(1):157-66. PMC: 4701850. DOI: 10.1210/jc.2015-3167. View

16.

Zheng H, Sigal R, Coyle D, Bai Z, Johnston A, Elliott J . Comparative efficacy and safety of antihyperglycemic drug classes for patients with type 2 diabetes following failure with metformin monotherapy: A systematic review and network meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021; 38(4):e3515. DOI: 10.1002/dmrr.3515. View

17.

Arnott C, Fletcher R, Neal B . Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk. Heart Fail Clin. 2022; 18(4):645-654. DOI: 10.1016/j.hfc.2022.03.008. View

18.

Cao H, Rao X, Jia J, Yan T, Li D . Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2022; 60(3):325-335. DOI: 10.1007/s00592-022-01989-7. View

19.

BERGSTROM W, WALLACE W . Bone as a sodium and potassium reservoir. J Clin Invest. 1954; 33(6):867-73. PMC: 438522. DOI: 10.1172/JCI102959. View

20.

Han C, Qu C . Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis. J Cardiovasc Pharmacol. 2020; 75(4):351-357. DOI: 10.1097/FJC.0000000000000796. View